press release

December 21, 2020

- Strong Commercial and Medical Team in Place to Execute on Three Ongoing Global Launches and Advancement of Innovative Pipeline of RNAi Therapeutics – CAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 21, 2020 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial Officer where he will lead global ...

press release

December 15, 2020

− Product and Pipeline Goals Include Execution on Four Commercial Brands, One New NDA Filing, Two Phase 3 Data Readouts, Amongst Other Milestones – – New Clinical Data Presented from Phase 1 Monotherapy Study of ALN AGT Show Mean Reduction in 24 Hour Systolic Blood Pressure of Over 15 mm Hg – – New Highlighted Programs Include Investigational RNAi Therapeutics for ...

capella

December 14, 2020

On December 15th and 16th, 2020, we hosted a virtual R&D Day event showcasing Alnylam’s late stage clinical efforts, next wave programs, and platform advances. The Company also discussed its perspective on its transition toward achieving a self sustainable financial profile. The event included presentations from Alnylam management and key opinion leaders. To view a replay of the webcast, click ...

press release

December 8, 2020

CAMBRIDGE, Mass. (BUSINESS WIRE) Dec. 8, 2020 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on December 15 and 16, 2020. In addition to presentations from Alnylam senior leaders, the event will include presentations from the ...

press release

November 24, 2020

– First RNAi Therapeutic Approved in U.S. for Use in Both Children and Adults, and Third RNAi Medicine to Receive FDA Approval in Less than Three Years – – Approval Based on Results from Both ILLUMINATE A and ILLUMINATE B Phase 3 Studies, Demonstrating Clinically Significant Reductions in Urinary Oxalate and Encouraging Safety and Tolerability Across a Broad Spectrum of Patient ...

press release

November 5, 2020

− Achieved Third Quarter 2020 ONPATTRO® Global Net Product Revenue of $82.5 Million, Including Over 20% Quarterly U.S. Growth, with More Than 1,150 Patients on Commercial Product Worldwide – − Achieved Third Quarter 2020 GIVLAARI® Global Net Product Revenue of $16.7 Million, with More Than 150 Patients on Commercial Product Worldwide – – Received Positive Opinions for OXLUMO™ (lumasiran) and LEQVIO® ...

press release

August 17, 2020

CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 17, 2020 Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously announced $2 billion strategic financing collaboration to accelerate the advancement of RNAi therapeutics. Under the terms of the agreement, Alnylam will receive up to $150 ...

press release

August 6, 2020

− Achieved Second Quarter 2020 ONPATTRO® Global Net Product Revenues of $66.5 Million, with More Than 1,050 Patients on Commercial Product Worldwide – − Achieved Second Quarter 2020 GIVLAARI® Global Net Product Revenues of $11.0 Million with More Than 100 Patients on Commercial Product Worldwide – – Presented Complete Results from ILLUMINATE A Phase 3 Study of Lumasiran and Completed Filings ...

press release

August 6, 2020

- Greene to Pursue New Opportunities at End Q3, While Remaining a Consultant for Up to Two Years to Ensure Orderly Transition Yvonne Greenstreet to be Named President and Chief Operating Officer; Company Initiates Search for a Chief Commercial Officer CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 6, 2020 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that ...

press release

August 3, 2020

– Company Expects to Initiate a Phase 1 Study in Late 2020 – CAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 3, 2020 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase ...